Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Mitral valve disease in the United States: retrospective analysis of hospitalizations and surgical procedures using the National Inpatient Sample (World Congress on Heart Disease abstract)

Introduction

Valvular heart disease (VHDs), of which the mitral valve is frequently implicated, are collectively responsible for more than 20,000 annual deaths in the United States and the economic burden on the public health system due to VHDs is estimated in the billions of dollars.

Objective

The aim of this study was to assess the number of mitral valve disease hospitalizations and surgical procedures in the United States during the period 2010-2013.

Materials and Methods

Patient data were extracted from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS). The NIS is the largest publicly available all-payer inpatient healthcare database in the United States, containing a 20% stratified systematic random sample of discharges from all US community hospitals. The most recent 4 years of available data, 2010-2013, were used for this analysis. Patients diagnosed with mitral valve disease were identified using the appropriate International Classification of Diseases 9th revision (ICD-9) diagnosis codes. ICD-9 procedure codes were used to identify surgeries to repair or replace the mitral valve, including transcatheter mitral valve repair (TMVR), open repair, tissue graft, and synthetic replacement. Categorical variables were analyzed using the chi-squared test, while continuous variables were analyzed using a one-way analysis of variance (ANOVA) or independent samples t-test.

Results

There were 174,2587 discharge records in 2013 with a diagnosis of mitral valve disease. Using HCUP’s sampling weights, this extrapolates to 871,290 hospitalizations in the United States. This is a slight decrease from 2010, when there were 883,933 estimated hospitalizations. The mean age of patients hospitalized for mitral valve disease increased from 71.15 (95% CI: 71.08-71.23) years in 2010 to 71.68 (95% CI: 71.61-71.76) years in 2013 (p<0.0001). 61.7% of mitral valve hospitalizations were females in 2010 compared with 59.2% in 2013 (p<0.0001). Mitral valve surgical procedures increased from 35,111 procedures in 2010 to 38,030 procedures in 2013. Concurrently, the proportion of mitral valve disease patients that underwent a surgical procedure to repair or replace the mitral valve increased from 3.5% in 2010 to 3.9% in 2013 (p<0.0001). Among elderly patients ≥80 years of age, mitral valve disease represented an increasing proportion of all hospitalizations, increasing from 6.0% in 2010 to 6.6% in 2013. Patients with a primary diagnosis of mitral valve disease who underwent a mitral valve surgical procedure were younger on average than those with a primary diagnosis of mitral valve disease who did not undergo a surgical procedure: 64.50 (95% CI: 64.31-64.69) years vs. 70.73 (95% CI: 70.51-70.95) years (p<0.0001). Conclusions This study reveals that mitral valve disease is a considerable public health problem in the United States, particularly among older adults. During 2010-2013, an increasing proportion of hospitalized patients with mitral valve disease underwent surgical procedures to repair or replace the valve. Overall, the volume of mitral valve surgical procedures increased approximately 8.3% from 2010 to 2013.